Publications by authors named "Candy Robinson"

Claim this Profile
L
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Elizabeth O Hexner, Cynthia Serdikoff, Mahfuza Jan, Cezary R Swider, Candy Robinson

Blood· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
Ted L Underiner, Bruce Ruggeri, Lisa Aimone, Mark Albom, Thelma Angeles, Candy Robinson

Bioorg Med Chem Lett· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Reddeppareddy Dandu, Allison L Zulli, Edward R Bacon, Ted Underiner, Candy Robinson

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
Nadine C Becknell, Allison L Zulli, Thelma S Angeles, Shi Yang, Mark S Albom, Candy Robinson

Bioorg Med Chem Lett· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
Rabindranath Tripathy, Alyssa Reiboldt, Patricia A Messina, Mohamed Iqbal, Jasbir Singh, Candy Robinson

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.
Pawel Dobrzanski, Kathryn Hunter, Susan Jones-Bolin, Hong Chang, Candy Robinson

Cancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Diane E Gingrich, Dandu R Reddy, Mohamed A Iqbal, Jasbir Singh, Lisa D Aimone, Candy Robinson

J Med Chem· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Bruce Ruggeri, Jasbir Singh, Diane Gingrich, Thelma Angeles, Mark Albom, Candy Robinson

Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Bruce A Ruggeri, Candy Robinson, Thelma Angeles, John Wilkinson, Margie L Clapper

Clin Cancer Res· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis